Mm

MASCOT, Australia, March 15, 2010 - Boston Scientific Corporation (NYSE: BSX) announces that it received Australian Therapeutic Goods Administration (TGA) approval for its PROMUS(R) Element(TM) and TAXUS(R) Element(TM) Stent Systems, the Company's third-generation drug-eluting stent (DES) technology.

BARCELONA, Spain, February 15, 2010 - PEPCOM, Mobile World Congress -- Sonim Technologies, the manufacturer of the world's toughest phones, today announces the latest in its Xtreme Performance series, the Sonim XP2 Spirit - its first 3G mobile phone.

BRUSSELS - - CE Markings for Additional New Indications Further Validate Use of Abbott's Drug Eluting Stents in Treating a Range of High-Risk and Complex Patients Abbott (NYSE: ABT) today announced that both the XIENCE PRIME(TM) Everolimus Eluting Coronary Stent System(1) and the XIENCE V(R) Everolimus Eluting Coronary Stent System have received additional new CE Markings (Conformite Europeenne) covering the treatment of patients with diabetes.